PVRI2021 is an all-digital, monthly programme of cutting edge science
In light of the global health and safety recommendations, we will deliver our Annual World Congress in a digital format, in lieu of an in-person event, that was due to take place in January 2021. An ambitious programme entitled 'PVRI2021' has been put together by the Scientific Organising Committee and will feature monthly live sessions of the highest quality scientific content.
World Pulmonary Hypertension Day: Inaugural IDDI Webinar
The PVRI are delighted to announce that Dr. Martine Rothblatt has agreed to deliver a keynote presentation as part of an inaugural IDDI webinar on World Pulmonary Hypertension Day. The digital event will take place on 5 May 2021 at 15:00BST.
We are pleased to announce a series of digital sessions that continue the fantastic work of the PVRI for our global members and young scientists. In the absence of in-person meetings and symposia, this series will enable us to stay in contact with our worldwide community, but also allow us to continue to explore and discuss important new research.
During the live sessions, there will be ample time set aside for Q&A to encourage active participation from our audience. All presentations will be available to download after the event.
Registration to the each of the monthly sessions will be free for all PVRI members. You can log in here to check the status of your PVRI membership.
Abstract submissions
The PVRI is delighted to announce that we are now accepting abstract submissions for our digital programme, PVRI2021.
Abstract submission should be emailed, as a Word document (or pdf), Arial font 11, with no more than 300 words (abstract title, authors and institutions are not to be considered in calculating the wordage), to: Admin@pvrinstitute.org.
A 3 minute (maximum), 3 slide (maximum) presentation should accompany your submission, describing your work. This should be recorded using Microsoft Powerpoint's presentation recording tool. Details for this can be found here.
The 3-minute presentation will be featured on the PVRI website and promoted in our secure discussion forum and abstract programme. The main purpose of this presentation is to act as a supporting commentary that encourages discussion within the PVRI community. The presentation will be displayed throughout the year and can be updated as the author pleases. The intention of this new feature is to replace the in-person, moderated ‘walk-around’ at our live events.
All correspondence relating to abstracts will be undertaken by email with the first named author / registered presenter, so it is their responsibility to communicate any relevant information regarding the submitted abstract and the congress to the other authors.
The accuracy of the submitted abstract is the responsibility of the authors, so authors should prepare and proofread their abstracts carefully before submitting to ensure it is the final version.
All accepted abstracts will be published in our journal, Pulmonary Circulation.
There is no fee for abstract submission but you must have an active PVRI membership.
Patricia Thistlethwaite, University of California, San Diego, USA (basic)
Stephan Rosenkranz, University of Cologne, Germany (clinical)
Scientific committee members
Sebastien Bonnet, Laval University, Canada
Allan Lawrie, University of Sheffield, UK
Stelios Orfanos, University of Athens Medical School, Greece
Rogerio Souza, University of São Paulo, Brazil
Rebecca Vanderpool, University of Arizona College of Medicine – Tucson, USA
Senior advisor
Werner Seeger, PVRI President 2020/21, Justus-Liebig-University Giessen, Germany
Scientific programme
Webinar 1 // 27 January 2021
Around the globe: Global burden of pulmonary hypertension
Presentations:
The view of the World Heart Federation (WHF)
Role of WHO/NCDA in promoting global health with a focus on cardiovascular disease
Update on the Global Burden of PH Project of the Institute for Health Metrics and Evaluation (IHME)
PVRI GoDeep: Perspectives of a global meta-registry
Best abstract
Best abstract
Webinar 2 // 24 February 2021
Keynote lecture session 2021
Presentations:
Keynote lecture 1: mHealth and wearables: Is this the dawn of a new age for cardiovascular medicine?
Keynote lecture 2: Sheila Glennis Haworth Memorial Lecture
Best abstract
Best abstract
Best abstract
Webinar 3 // 24 March 2021
Connection between CoViD-19 and pulmonary vascular disease
Presentations:
SARS-1, MERS, SARS-2 and more: Are coronavirus infections an ubiquitous part of our lives?
Endothelitis and aberrant angiogenesis: Mechanisms of COVID-19 induced vascular injury
Venous thromboembolism in COVID-19: Prevalence and clinical picture
ACE-II receptors: Modulation of PVD in COVID-19?
Best abstract
Best abstract
Webinar 4 // 28 April 2021
Virtual poster discussion session 1
Presentations:
Round 1: Basic – 6 posters
Round 2: Clinical – 6 posters
World Pulmonary Hypertension Day: Inaugural IDDI Webinar // 5 May 2021
Presentations:
Keynote presentation by Dr Martine Rothblatt
Webinar 5 // 26 May 2021
Novel imaging approaches in pulmonary hypertension patients
Presentations:
Update from the Fleischner Society Task Force for imaging in pulmonary hypertension
Molecular imaging of pulmonary vascular disease using microvascular endothelial cell ligands
MRI to assess pulmonary vascular changes and PH progression
Xenon magnetic resonance imaging signatures of PH
Synchrotron-based phase contrast micro-CT imaging of pulmonary vascular disease in human tissue and animal models
Webinar 6 // 23 June 2021
Joint Symposium with the ESC: The pulmonary circulation in the heart failure syndrome
Presentations:
The right ventricle in HFpEF
Genetic aspects in Group2 PH
Exercise haemodynamics in heart failure: What can we learn from invasive CPET?
Systemic consequences and interorgan cross-talk in heart failure and PH
Best abstract
Best abstract
Webinar 7 // 28 July 2021
Pro-Con debate session 1
Presentations:
Topic A: Role of pulmonary vascular pruning in PAH
PRO: A hopeless cause: The pulmonary vasculature is largely gone and irredeemable in PAH
CON: Remnants of lost pulmonary vasculature may be re-engaged in PAH
Topic B: Treatment of patients with mild PAH
PRO: Patients with mild pulmonary hypertension (mPAP 21-24) should be treated with PAH approved drugs
CON: Patients with mild pulmonary hypertension (mPAP 21-24) should NOT be treated with PAH approved drugs
Webinar 8 // 25 August 2021
The notch receptors: Multi-regulators of PAH development
Presentations:
Role of notch1 in experimental pulmonary hypertension
Notch-BMPR interactions in endothelium in PAH
Notch3 is a driver and biomarker for PAH
Notch3 lineage and pulmonary vasculopathy
Webinar 9 // 29 September 2021
Beyond DNA: The unseen genome and novel omics approaches to PH
Presentations:
MicroRNAs and IncRNAs in right heart hypertrophy and failure
LncRNA as biomarkers/therapeutic agents for pulmonary diseases - prospective view
Epigenomics in pulmonary vascular remodelling
Integrative analysis of cell state changes with peripheral protein biomarkers
Novel omics approaches: clinical utility in PAH
Webinar 10 // 27 October 2021
Joint symposium with the ISHLT: End-stage PAH - how and what do we do in 2021?
Presentations:
When should a PH patient be considered for lung transplant?
Atrial septum defect creation or mechanical support for end-stage PAH
Lung and Heart-lung Transplant in 2021 – how well do PAH patients do?
Pluripotent stem cell-based approaches and the future of artificial lungs
Timing and extent of ventricular reverse remodelling after lung transplant for PH
Webinar 11 // 24 November 2021
Machine learning and artificial intelligence approaches for PH: From screening to novel drug targets
Presentations:
Looking beyond the hype: Applied AI and machine learning in translational medicine
Computational network pharmacology in cardiovascular disease: Leveraging big data
Utilising artificial intelligence to screen and diagnose iPAH
Best abstract
Best abstract
Webinar 12 // 15 December 2021
Pro-Con debate session 2: Medical vs. surgical or interventional therapy for CTEPH
Presentations:
PRO: Riociguat should be given to all CTEPH patients, regardless of timing of PEA/BPA
CON: Riociguat should be given only to patients with inoperable or residual CTEPH after PEA/BPA
Best abstract
Best abstract
Best abstract
Best abstract
Best abstract
Webinar 13 // 26 January 2022
Virtual poster discussion session 2
Presentations:
Novel TRAF2 variant and KDR deletion are implicated in the pathogenesis of pulmonary arterial hypertension
Loss of Estrogen Receptor Alpha (ERα) Worsens Hemodynamic Alterations and Right Ventricular (RV) Adaptation in Female Rats with Pulmonary Hypertension (PH)
Breast cancer and heritable PAH due to BMPR2 mutation: an unexpected discovery
Smooth Muscle Tsc2 deficiency leads to spontaneous pulmonary hypertension and represents attractive molecular target for therapeutic intervention
Identification of ADORA1-PDE10A Complex Formation and Its Bidirectional Regulation of Intracellular Cyclic AMP Levels as a Novel Therapeutic
Downregulation of adenylate kinase 4 (AK4) improves the mitochondrial respiration and inhibits the glycolytic switch of pulmonary arterial smooth muscle cells
Association between Leflunomide and Pulmonary Hypertension
The Estimand Framework in PAH Clinical Trials
Risk stratification in pulmonary hypertension due to chronic obstructive pulmonary disease
Small pulmonary vessels in severe pulmonary hypertension associated with chronic lung disease
A Phase 1, open-label, crossover study of inhaled seralutinib to assess potential effects on the pharmacokinetics (PK) of cytochrome P450 (CYP) and transporter substrates in healthy subjects
Cardiac MRI and risk stratification in pulmonary arterial hypertension: evaluation of ESC/ERS thresholds for right atrial area
Webinar 14 // 23 February 2022
Bone marrow modulation of pulmonary vascular disease
Presentations:
Role of bone marrow in the pathogenesis of PAH
Role of bone marrow in the right ventricle remodelling
Reversal of PH by whole bone marrow transplantation in BMPR2 deficient mice
Bone marrow dependency of cigarette smoke-induced PH versus emphysema
Homologous bone marrow transplantation prevents the development of PAH in patients with severe scleroderma
Webinar 15 // 30 March 2022
Aging and pulmonary hypertension: An endemic at the horizon?
Presentations:
Age-dependent prevalence of PH in the general population
Senescence mechanisms and pulmonary vascular aging
Metabolic syndrome and obesity leads to age-related PH
Genetics and epigenetics in age-related PH
Best abstract
Best abstract
Webinar 16 // 27 April 2022
The association between cancer and PH: A tale of two diseases
Presentations:
Cancer induced PH: Embolism as a major inducer
Cancer induced PH: Microenvironmental cancer niche as a major inducer
Cancer therapies induced PH
Cancer related signalling mechanisms underlying PH development
Best abstract
Best abstract
Webinar 17 // 25 May 2022
Professor Sheila Glennis Haworth Memorial Symposium on Paediatric PH
Presentations:
Genetics of pulmonary arterial hypertension: What we can learn by studying children with and without congenital heart disease
Therapeutic options in advanced PVD: Potts shunt versus lung transplantation
Stem cells and regenerative medicine for neonatal lung disease: Implications for COPD
Assessment of operability in patients with congenital heart disease and PAH: Fallacies and pitfalls